It seems clear that MSB has the potential to be $50 plus a share.
To sell out now after all this time for a few extra bucks on the s.p.would be heartbreaking.
They have been clever and diligent in patent applications, they know how important this is. stem cells cant be patented so they have
zipped up what they believe they can with all their might.
Apart from being ahead of the pack in trials, their value is in the I.P. this is what Pharma (may) want more than anything.
The ability to enforce these into the future will be important, however first out of the blocks may be equally as important.
Just m.h.o.,
It doesnt seem like the efficacy will dissapoint.
Analysis of the EAP, page-326
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.25 |
Change
0.035(2.89%) |
Mkt cap ! $1.421B | |||
| Open | High | Low | Value | Volume |
| $1.21 | $1.25 | $1.18 | $4.096M | 3.347M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 22000 | $1.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.25 | 36989 | 4 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |